Search
Sumario de resultados
TIpos de contenido
Fecha
-
New#AseBioID24 | "These ecosystem events are the best way to develop relationships with inves...
We analyze the challenges and opportunities of the biotechnology sector in areas such as financing and driving its disruptive innovations, led by Antonio López, CEO of SILO, Silver Sponsor of the
-
NewORYZON secures another important patent for its lead CNS asset, vafidemstat
Has received “Intention to Grant” from the European Patent Office.
-
-
NewThe R&D investment of Spanish biotechnology increased by 13% in 2022, surpassing 2.5 billi...
According to the INE, when exclusively analyzing the figures in Companies, R&D investment has increased by 18% compared to 2021: 1.223 billion euros compared to 1.038 billion euros, respectively.
-
-
New#NewAseBioMember | “AseBio is an important industry association in Spain, representing the...
Meet Owkin, our new member. We talked to its Francisco Miguel Torres, Partnerships Director, Southern Europe.
-
Press releaseAseBio launches the Food Innovation Working Group to boost the biotechnological potential ...
The Spanish agri-food sector has undeniable strategic value for the national economy due to its impact on GDP: Spain ranks as the eighth global agri-food power. Within AseBio, over 25% of our members
-
NewThe "yes" from the European Parliament to the reform of pharmaceutical legislation jeopard...
Biotechnology has radically transformed the discovery of new drugs: 68% of the drugs currently in development globally are biotechnological.
-
Press release
The "yes" from the European Parliament to the reform of pharmaceutical legislation jeopard...
We consider that improvements have been made regarding the original proposal, but these continue to be insufficient for the protection, development, and promotion of biotechnological innovation in
-
EventWebinar: Preparing for IVDR Clinical Performance Studies
The webinar will focu on the critical aspects of designing and conducting In Vitro Diagnostic (IVD) performance studies under the stringent requirements of the EU IVDR and ISO 20916.
-
NewBiotechnology seeks solutions for Parkinson's, the second most common neurodegenerative di...
Parkinson's is an extremely debilitating disease, there is no cure, and we only have medications aimed at alleviating symptoms once the diagnosis has been made.
-
Press release
Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative di...
Approximately 10,000 new cases of Parkinson's are detected each year in Spain, with a total figure exceeding 150,000 individuals. Parkinson's is an extremely debilitating disease, there is no cure
-
EventAseBio Green Innovation Forum 2026
The sixth edition, organized by AseBio and the Salamanca City Council, will take place on April 21 at the Castilla y León Conference and Exhibition Centre.
-
EventWorld Orphan Drug Congress Europe
Strategy, Advocacy & Partnering for The Global Orphan Drug Industry.
-
New#NewAseBioMember | “AseBio is the perfect platform for company collaboration, research syn...
Meet Copal Scientific, our new member. We talked to its Mercedes Iriarte Cela, CEO.
-
New#NewAseBioMember | “AseBio represents a platform within the bioindustry ecosystem”
Meet Spinally Medical, our new member. We talked to its Carles García-Vitoria, Co-fundador & Chief Scientific Officer.
-
NewORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by N...
In combination with either atezolizumab or durvalumab.
-
New#AseBioID24 | "AseBio Investor Day is a unique meeting point for companies and investors s...
With the aim of analyzing the Spanish biotechnological ecosystem and delving into the challenges and opportunities it presents, we interviewed Susana de Antonio Horcajo, Head of Listing Spain at
-
-
NewRevolution in Pain Management straight from Spain: Introducing the Spinally Medical
Spinally Medical introduces FuturaLead™, a subarachnoid device for spinal cord stimulation aimed at patients suffering from chronic pain.
-
NewBiotechnology lays the groundwork for the present and future of healthcare and drives the ...
The health pipeline of AseBio includes 130 molecules for 150 indications being investigated by 40 national companies, with oncology as the majority area. Additionally, 47 AseBio partner entities are
